• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Number of product manufacturing facilities site inspections which occurred during the month

Dictionary: Number of OBP product manufacturing facilities site inspections which occurred during the month. OBP review staff participates in most pre-approval inspections and many surveillance inspections of manufacturing facilities. For complex products, such as therapeutic protein and monoclonal antibody products, it is important for OBP reviewers to participate in the assessment of the manufacturing process and controls at the facility.


These measures have been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct 2009N/A5
Nov 2009N/A5
Dec 2009N/A0
Jan 2010N/A2
Feb 2010N/A2
Mar 2010N/A3
Apr 2010N/A2
May 2010N/A2
Jun 2010N/A1
Jul 2010N/A0
Aug 2010N/A1
Sep 2010N/A1

Number of pre-, post-, and during inspection meetings which occurred during the month

Dictionary: Number of pre-, post-, and during inspection meetings with ORA and CDER’s Office of Compliance (OC) Division of Manufacturing and Product Quality (DMPQ) which occurred during the month. For complex products, such as therapeutic protein and monoclonal antibody products, it is important for OBP reviewers to participate in the assessment of the manufacturing process and controls at the facility. This participation involves meetings. In addition, for facilities where OBP does not participate in the inspection, meetings convey issues to be considered during inspections.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct 2009N/A9
Nov 2009N/A4
Dec 2009N/A0
Jan 2010N/A2
Feb 2010N/A6
Mar 2010N/A6
Apr 2010N/A10
May 2010N/A1
Jun 2010N/A7
Jul 2010N/A2
Aug 2010N/A2
Sep 2010N/A1

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.